Building 7
Kiryat Atidim
Tel Aviv 6158002
Israel
972 77 331 0156
https://www.chemomab.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director | 330k | N/A | 1982 |
Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer | 322k | N/A | 1971 |
Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development | 850k | N/A | 1969 |
Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | N/A | N/A | N/A |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.